David Snyder, MD
Pulmonary Disease · Decatur, GANPI 1053395145
Payments from drug & device makers
Across 182 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$586
- Boehringer Ingelheim$314
- AstraZeneca$288
- Electromed, Inc.$243
- Grifols USA, LLC$241
- United Therapeutics Corporation$168
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,67399%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $586 |
| Boehringer Ingelheim | 13 | $314 |
| AstraZeneca | 16 | $288 |
| Electromed, Inc. | 18 | $243 |
| Grifols USA, LLC | 12 | $241 |
| United Therapeutics Corporation | 8 | $168 |
| Inspire Medical Systems, Inc. | 4 | $157 |
| Jazz Pharmaceuticals Inc. | 6 | $145 |
| Mylan Specialty L.p. | 7 | $134 |
| Actelion Pharmaceuticals US, Inc. | 6 | $127 |
| Amgen | 5 | $114 |
| Baxter Healthcare | 5 | $111 |
| Philips North America LLC | 5 | $106 |
| Vifor Pharma, Inc. | 4 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| Bayer | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $60 |
| Shire North American Group Inc | 3 | $54 |
| Insmed, Inc. | 2 | $50 |
| Merck | 2 | $45 |
| Melinta Therapeutics, LLC | 2 | $44 |
| Verona Pharma, Inc. | 1 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $28 |
| AbbVie | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Vapotherm Inc | 1 | $22 |
| Sanofi | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Circassia Inc. | 1 | $15 |
How this compares
$3,701 in reported general payments places this provider in the 40th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 59 | $636,996 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 739 | $606,819 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $263,554 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 254 | $146,325 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 116 | $70,262 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $66,586 |
| Breo ElliptaFluticasone/Vilanterol | 136 | $65,412 |
| Spiriva RespimatTiotropium Bromide | 76 | $54,682 |
| XareltoRivaroxaban | 30 | $21,670 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $17,726 |
| EliquisApixaban | 30 | $15,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 484 | $9,927 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,538 |
| BelsomraSuvorexant | 21 | $9,187 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $4,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $586 | $836,2821,178 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $314 | $761,940251 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $86 | $263,55413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $288 | $76,124107 claims |
| Johnson & JohnsonXarelto | $16 | $21,67030 claims |
| PfizerEliquis | $17 | $15,42430 claims |
| MerckBelsomra, Dulera | $45 | $13,08633 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $60 | $32213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Decatur
- David MillerDecatur$206K
- Thomas DemariniDecatur$59K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.